{
    "ticker": "CRBU",
    "name": "Caribou Biosciences, Inc.",
    "description": "Caribou Biosciences, Inc. is a biotechnology company focused on developing transformative genome-editing technologies. Founded in 2011, Caribou is a pioneer in the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) field, leveraging its innovative genome-editing platform to create therapies for a range of genetic diseases. The company's proprietary technology enables precise modifications of DNA in living organisms, which has wide applications in therapeutics, agriculture, and industrial biotechnology. Caribou is particularly focused on advancing its CAR-T (Chimeric Antigen Receptor T-cell) therapies for cancer treatment, aiming to improve the effectiveness and accessibility of immunotherapies. With a robust pipeline of product candidates, Caribou is committed to translating scientific breakthroughs into real-world solutions that can significantly impact patient care. The company collaborates with academic institutions and industry partners to further its research and development efforts, contributing to the growth of the biotech landscape. Caribou's mission is to harness the power of CRISPR technology to create a healthier future for individuals and communities around the globe.",
    "industry": [
        "Biotechnology",
        "Genetics"
    ],
    "headquarters": "Berkeley, California, USA",
    "founded": "2011",
    "website": "https://www.cariboubio.com",
    "ceo": "Rachel Haurwitz",
    "social_media": {
        "twitter": "https://twitter.com/CaribouBio",
        "linkedin": "https://www.linkedin.com/company/caribou-biosciences/"
    },
    "investor_relations": "https://investors.cariboubio.com",
    "key_executives": [
        {
            "name": "Rachel Haurwitz",
            "position": "CEO"
        },
        {
            "name": "John McCauley",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CAR-T Therapies",
                "Gene Editing Products"
            ]
        },
        {
            "category": "Research Tools",
            "products": [
                "CRISPR Kits",
                "Gene Editing Reagents"
            ]
        }
    ],
    "seo": {
        "meta_title": "Caribou Biosciences, Inc. | Pioneer in Genome Editing Technologies",
        "meta_description": "Explore Caribou Biosciences, Inc., a leader in CRISPR gene editing technology. Learn about their innovative therapies and commitment to advancing biotechnology.",
        "keywords": [
            "Caribou Biosciences",
            "CRISPR",
            "Gene Editing",
            "Biotechnology",
            "CAR-T",
            "Cancer Therapy"
        ]
    },
    "faq": [
        {
            "question": "What is Caribou Biosciences known for?",
            "answer": "Caribou Biosciences is known for its pioneering work in CRISPR gene editing technologies and developing innovative therapies for genetic diseases."
        },
        {
            "question": "Who is the CEO of Caribou Biosciences?",
            "answer": "Rachel Haurwitz is the CEO of Caribou Biosciences, Inc."
        },
        {
            "question": "Where is Caribou Biosciences headquartered?",
            "answer": "Caribou Biosciences is headquartered in Berkeley, California, USA."
        },
        {
            "question": "What are the main products of Caribou Biosciences?",
            "answer": "Caribou's main products include CAR-T therapies for cancer treatment and research tools for gene editing."
        },
        {
            "question": "When was Caribou Biosciences founded?",
            "answer": "Caribou Biosciences was founded in 2011."
        }
    ],
    "competitors": [
        "EDIT",
        "NTLA",
        "CRSP",
        "SGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}